Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (191-200 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecanJessica M van der Bol, Ron H J Mathijssen, Geert-Jan M Creemers, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction studyJessica M van der Bol, Walter J Loos, Floris A de Jong, et al.
The Lancet. Oncology|September 8, 2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trialPenella J Woll, Peter Reichardt, Axel Le Cesne, et al.
Molecular Cancer|November 19, 2015
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathwayMarijn T M van Jaarsveld, Patricia F van Kuijk, Antonius W M Boersma, et al.
BMC Cancer|June 15, 2014
MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3αCaroline M M Gits, Patricia F van Kuijk, Jonneke C W M de Rijck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapyAnne-Joy M de Graan, Walter J Loos, Lena E Friberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancerAlbert J Ten Tije, Jaap Verweij, Alex Sparreboom, et al.
Histopathology|August 19, 2010
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumoursMarco Novelli, Sabrina Rossi, Manuel Rodriguez-Justo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyMartine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2006
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter, Raf Sciot, Axel Le Cesne, et al.
Pageof 24

Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecanJessica M van der Bol, Ron H J Mathijssen, Geert-Jan M Creemers, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction studyJessica M van der Bol, Walter J Loos, Floris A de Jong, et al.
The Lancet. Oncology|September 8, 2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trialPenella J Woll, Peter Reichardt, Axel Le Cesne, et al.
Molecular Cancer|November 19, 2015
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathwayMarijn T M van Jaarsveld, Patricia F van Kuijk, Antonius W M Boersma, et al.
BMC Cancer|June 15, 2014
MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3αCaroline M M Gits, Patricia F van Kuijk, Jonneke C W M de Rijck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapyAnne-Joy M de Graan, Walter J Loos, Lena E Friberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancerAlbert J Ten Tije, Jaap Verweij, Alex Sparreboom, et al.
Histopathology|August 19, 2010
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumoursMarco Novelli, Sabrina Rossi, Manuel Rodriguez-Justo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyMartine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2006
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter, Raf Sciot, Axel Le Cesne, et al.
Pageof 24